Table 1 Baseline characteristics and treatment outcome of TNBC patients treated with neoadjuvant chemotherapy (N = 54)
Age at diagnosis | |
|---|---|
median (min-max) [IQrange] | 49.2 (26.7–76.6) [45.3–60.3] |
<49 | 25 (46.3) |
≥49 | 29 (53.7) |
Stage | |
II | 18 (33.3) |
III | 36 (66.7) |
Grade | |
1–2 | 22 (40.7) |
3 | 32 (59.3) |
Ki-67 | |
median (min-max) [IQrange] | 70.0 (10.0–90.0) [43.7–80.0] |
Chemotherapy | |
Sequential | 47 (87.0) |
Concomitant | 7 (13.0) |
pCR | |
No | 37 (68.5) |
Yes | 17 (31.5) |
BMI | |
median (min-max) [IQrange] | 23.9 (17.5–41.6) [21.7–25.9] |
< 25 | 31 (57.4) |
≥ 25 | 23 (42.6) |
γ-H2AX | |
Low | 25 (46.3) |
High | 29 (53.7) |
pChk1 | |
Neg | 16 (29.6) |
Pos | 38 (70.4) |